Current Role at Stanford

Clinical Research Manager

Education & Certifications

  • Professional Certificate, UCSC Extension, Regulatory Affairs (2019)
  • Master of Technology (Research), National Institute of Technology Karnataka (NITK), India, Industrial Biotechnology (2013)

Service, Volunteer and Community Work

  • Administrative Support Volunteer, HERS Breast Cancer Foundation (May 28, 2018 - November 30, 2018)

    Location

    Fremont, CA

Contact

  • Work
    pavim@stanford.edu
    University - Staff Department: Psych/Public Mental Health & Population Sciences Position: Clinical Rsch Mgr 1
    • 401 QUARRY RD
    • STANFORD,  California  94305 

Additional Info

Work Experience

  • Scientist Level I- Analytical Development, Zumutor Biologics (October 1, 2013 - November 30, 2017)

    Early Stage Drug Discovery Programs- Oncology

    Location

    Bengaluru, India

  • Regulatory Compliance Intern, CliniOps (April 1, 2019 - June 15, 2019)

    Assisted in implementing quality management system for their clinical operations process

    Location

    Fremont, CA

Professional Affiliations and Activities

  • Member, Regulatory Affairs Professional Society (2019 - Present)

All Publications

  • Microbial expression of Exendin-4 analog and its efficacy in mice model BIOLOGICALS Kodaganti, B., Mukunda, P., Dakshinamurthy, P., Manjunath, Y., Shenoy, B., Kamanagowda, V., Natarajan, B., Maliwalave, A., Unnikrishnan, D., Murugesan, S., Halan, V., Ghosh, M., Maity, S. 2017; 48: 82–91

    Abstract

    Exendin-4 is a GLP 1 agonist incretin-mimetic peptide hormone comprising 39 amino acids. Exenatide (Byetta®) is a chemically synthesized version of Exendin-4 with an additional C-terminal amidation. Exenatide acts as a GLP-1 receptor agonist. This paper illustrates the method adopted for cloning, fermentation and purification of recombinant Exendin-4 analog expressed in Escherichia coli. The biologically expressed analog was extensively characterized using different orthogonal methods to confirm their biological activity and physicochemical properties. It was observed that the expressed analog showed comparable functional properties as that of Byetta® irrespective of their modes of development. Further, in vivo efficacy of the recombinant Exendin-4 analog was studied in Oral Glucose Tolerance Test (OGTT) in mice models. Byetta® and Exendin-4 analog treated groups showed comparable glucose lowering activity in the OGTT model.

    View details for DOI 10.1016/j.biologicals.2017.05.002

    View details for Web of Science ID 000407535800011

    View details for PubMedID 28554726

  • Intracellular delivery of antibodies by chimeric Sesbania mosaic virus (SeMV) virus like particles SCIENTIFIC REPORTS Abraham, A., Natraj, U., Karande, A. A., Gulati, A., Murthy, M. N., Murugesan, S., Mukunda, P., Savithri, H. S. 2016; 6: 21803

    Abstract

    The therapeutic potential of antibodies has not been fully exploited as they fail to cross cell membrane. In this article, we have tested the possibility of using plant virus based nanoparticles for intracellular delivery of antibodies. For this purpose, Sesbania mosaic virus coat protein (CP) was genetically engineered with the B domain of Staphylococcus aureus protein A (SpA) at the βH-βI loop, to generate SeMV loop B (SLB), which self-assembled to virus like particles (VLPs) with 43 times higher affinity towards antibodies. CP and SLB could internalize into various types of mammalian cells and SLB could efficiently deliver three different monoclonal antibodies-D6F10 (targeting abrin), anti-α-tubulin (targeting intracellular tubulin) and Herclon (against HER2 receptor) inside the cells. Such a mode of delivery was much more effective than antibodies alone treatment. These results highlight the potential of SLB as a universal nanocarrier for intracellular delivery of antibodies.

    View details for DOI 10.1038/srep21803

    View details for Web of Science ID 000370863300001

    View details for PubMedID 26905902

    View details for PubMedCentralID PMC4764859

https://orcid.org/0009-0003-1020-2650